Narayana Hrudayalaya Limited
₹1,719.70+₹5.45 (+0.3%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹38,566 Cr
- P/E
- 83.0x
- EV / EBITDA
- 54.0x
- Revenue
- ₹3,590 Cr
- Net margin
- 13.0%
- ROCE
- 21.4%
Price chart
Technical chartScreen technicals →-4.1% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -4.1%
- 3M
- -17.3%
- 6M
- -2.6%
- 1Y
- -4.1%
- 5Y
- +215.4%
52-week range
Day change +₹5.45 (+0.3%) from ₹1,714 to ₹1,720 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in NH, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Strong 5-year net profit CAGR of 44.3%
Concerns1
- Negative free cash flow (₹232 Cr)
Rule-based from financial data. Not advice.
About the company
Narayana Hrudayalaya Limited provides medical and healthcare services in India and the Cayman Islands. It operates through the Medical and Healthcare Related Services; and Others segments.
Read moreShow less
Narayana Hrudayalaya Limited provides medical and healthcare services in India and the Cayman Islands. It operates through the Medical and Healthcare Related Services; and Others segments. The company offers oncology, anesthesiology, audiology, blood bank, oncoplastic surgery, cardiac surgery, cardiology, clinical genetics, clinical immunology, clinical nutrition and dietetics, clinical psychology, congenital adult heart disease, cosmetology, cranio-maxillofacial surgery, critical care medicine, dental, dermatology, pediatrics, diabetology, ENT, emergency medicine, endocrinology, family medicine, general and GI surgery, general medicine and surgery, geriatric medicine, gynecology, hematology, headache and facial pain management, transplant, infectious diseases, neurology, radiology, hepatobiliary surgery, gastroenterology, minimal access GI and bariatric surgery, neonatology, nephrology, neuro-otology, neuro-rehabilitation, neurosurgery and spine surgery, and nuclear medicine services. It also provides ophthalmology, orthopedics and joint replacement, pain management and palliative care, pathology, perinatology and fetal intervention, physical medicine and rehabilitation, physiotherapy and physical rehabilitation, plastic surgery, psychiatry, pulmonology, reproductive medicine, rheumatology, renal science, speech and swallow rehabilitation, spine surgery, thoracic and vascular surgery, ultrasonology, urology, and other services. In addition, the company acquires, owns, and operates hospitals, clinics, health centers, diagnostic centers, and nursing homes. Further, it provides health insurance, consultancy services in the field of healthcare and hospitals, and IT services related to healthcare. Additionally, the company engages in investment activities; and develops software related to the healthcare industry. Narayana Hrudayalaya Limited was incorporated in 2000 and is headquartered in Bengaluru, India.
- Sector
- Healthcare
- Shares outstanding
- 20.4 Cr shares
- ISIN
- INE410P01011
- BSE code
- 539551
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹38,566 Cr
- P/E
- 83.0x
- P/B
- 16.6x
- EV / EBITDA
- 54.0x
- EV / Sales
- 12.1x
- P/S
- 11.8x
- Earnings yield
- 1.2%
- 52-week high
- ₹2,079.35
- 52-week low
- ₹1,605.65
Profitability
- Operating margin
- 18.6%
- Net margin
- 13.0%
- EBITDA margin
- 22.3%
- ROE
- 23.1%
- ROCE
- 21.4%
- ROA
- 12.2%
- Dividend payout
- 19.0%
- Tax rate
- 16.0%
- Other income, % of PBT
- 23.9%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹3,590 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 9.9%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 7.8%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹729 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 23.8%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 1.4%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 44.3%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹542 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.0%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹159 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 25.9%
Solvency and efficiency
- Current ratio
- 3.07
- Debt / Equity
- 0.55
- Debt / Assets
- 0.29
- Debt / EBITDA
- 1.39
- Interest coverage
- 9.37
- Financial leverage
- 1.90
- CFO / Net profit
- 1.28
- Cash / Market cap
- 2.5%
- Cash per share
- ₹47.09
- Asset turnover
- 0.93
- Fixed asset turnover
- 2.21
- Capital intensity
- 0.45
- Debtor days
- 21 days
- Inventory turnover
- 13.04
- Cash conversion cycle
- -143 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹12 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹2,905 Cr |
| Sales | Operating profit | ₹685 Cr |
| Operating profit | Interest | ₹98 Cr |
| Operating profit | Depreciation | ₹169 Cr |
| Operating profit | Profit before tax | ₹418 Cr |
| Other income | Profit before tax | ₹139 Cr |
| Profit before tax | Tax and other | ₹126 Cr |
| Profit before tax | Net profit | ₹431 Cr |
Revenue and net profit
Revenue grew 9.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,655 Cr | -₹79 Cr |
| FY2022 | ₹2,412 Cr | ₹134 Cr |
| FY2023 | ₹2,965 Cr | ₹266 Cr |
| FY2024 | ₹3,266 Cr | ₹425 Cr |
| FY2025 | ₹3,590 Cr | ₹431 Cr |
Cash flows
FY2025: ₹523 Cr from operations, -₹232 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹123 Cr | ₹111 Cr |
| FY2022 | ₹246 Cr | ₹129 Cr |
| FY2023 | ₹516 Cr | -₹105 Cr |
| FY2024 | ₹542 Cr | -₹219 Cr |
| FY2025 | ₹523 Cr | -₹232 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹3,590 Cr+9.9%1Y
- Net profit
- ₹431 Cr+1.4%1Y
- Cash from operations
- ₹523 Cr
- Free cash flow
- -₹232 Cr
- Revenue CAGR, 5Y
- 7.8%
- EBITDA CAGR, 5Y
- 20.5%
- Net profit CAGR, 5Y
- 44.3%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹3,590 Cr | ₹685 Cr | — | ₹431 Cr | ₹523 Cr | -₹232 Cr | 19.7% | +9.9% | +1.4% |
Monthly returns
Month-by-month returns of NH across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹4,502 Cr |
| Equity capital | ₹204 Cr |
| Reserves | ₹1,981 Cr |
| Borrowings | ₹1,595 Cr |
| Other liabilities | ₹722 Cr |
| Assets | ₹4,502 Cr |
| Fixed assets | ₹2,325 Cr |
| Capital work in progress | ₹43 Cr |
| Investments | ₹1,166 Cr |
| Other assets | ₹967 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
NH trades at 83.0x earnings against a peer median of 52.6x (a 58% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Narayana Hrudayalaya LimitedNHthis companyP/E ↑ premium | ₹38,566 Cr | 83.0x | 16.6x | 23.1% | 54.0x |
| Procter & Gamble Hygiene & Health Care Ltd.PGHH | ₹40,121 Cr | 48.5x | 43.1x | — | — |
| GlaxoSmithkline Pharmaceuticals Ltd.GLAXO | ₹40,108 Cr | 42.4x | 23.5x | — | — |
| Ipca Laboratories Ltd.IPCALAB | ₹38,240 Cr | 39.5x | 5.2x | 8.3% | 32.5x |
| Anthem Biosciences LimitedANTHEM | ₹35,376 Cr | 66.2x | 12.4x | 19.4% | 61.4x |
| Ajanta Pharma Ltd.AJANTPHARM | ₹34,058 Cr | 35.8x | 8.3x | 23.6% | 27.3x |
| Global Health LimitedMEDANTA | ₹31,404 Cr | 59.8x | 8.3x | 16.0% | 37.3x |
| Aster DM Healthcare LimitedASTERDM | ₹31,356 Cr | 92.8x | 7.1x | 5.4% | 78.2x |
| Emcure Pharmaceuticals LimitedEMCURE | ₹29,399 Cr | 67.9x | 9.1x | 8.3% | 53.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
NH since 1 January, against earlier years.
Historical volatility
NH's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | -1.0% |
| FY2022 | 11.0% |
| FY2023 | 17.0% |
| FY2024 | 19.0% |
| FY2025 | 19.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹3,590 Cr |
| Costs | |
| Interest | ₹98 Cr |
| Expenses | ₹2,905 Cr |
| Operating profitOperating Profit | ₹685 Cr |
| Other income and charges | |
| Profit before tax | ₹557 Cr |
| Tax | |
| Net profitNet Profit | ₹431 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹4,502 Cr |
| Equity capitalEquity Capital | ₹204 Cr |
| Reserves | ₹1,981 Cr |
| Borrowings | ₹1,595 Cr |
| Other liabilitiesOther Liabilities | ₹722 Cr |
| AssetsTotal Assets | ₹4,502 Cr |
| Fixed assetsFixed Assets | ₹2,325 Cr |
| Capital work in progressCWIP | ₹43 Cr |
| Investments | ₹1,166 Cr |
| Other assetsOther Assets | ₹967 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹523 Cr |
| Investing cash flowCash from Investing Activity | -₹755 Cr |
| Financing cash flowCash from Financing Activity | ₹391 Cr |
| Change in cashNet Cash Flow | ₹159 Cr |
Learn while you research
Academy chapters picked for Narayana Hrudayalaya Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 83.0, learn when high multiples are justified.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read